Novel Bicyclic CCR5 Antagonists for Treatment of HIV/AIDS
Purdue University researchers developed Darunavir, brand name Prezista, a drug used to treat HIV infection. Prezista was developed by the pharmaceutical company Tibotec and is an OARAC recommended treatment option for treatment-naïve and treatment-experienced adults and adolescents. It is also used in patients with drug-resistant HIV. They have also developed a new generation of protease inhibitors that are exceedingly potent and maintain potency against multidrug resistant HIV-1 variants. Dr. Ghosh's laboratory has designed, synthesized, and evaluated several different series of compounds. These novel protease inhibitors show potent enzyme inhibitory, antiviral activity, and exceptional broad-spectrum activity against highly cross-resistant mutant.
Decreased adverse side effectsEffective against multidrug resistant HIV-1 variants Improved bioavailabilitySuperior pharmacokinetic properties
Medical/HealthcarePharmaceuticalsHIV/AIDS TreatmentDrug Development
Arun GhoshGhosh GroupPurdue Chemistry
United States
9,062,057
美国
